The ferocity of China’s biopharmaceutical investment boom this year – fuelled by record-breaking licensing of commercial rights to global giants…
Read More »Keytruda
China’s cost and efficiency advantages in drug development have been recognised at the world’s largest cancer research conference in the…
Read More »
Chinese biotech firm Akeso, whose cancer drug has been hailed as a breakthrough for the nation’s pharmaceutical industry, suffered a…
Read More »